Low-Level Laser Therapy Reduces Lung Inflammation in an Experimental Model of Chronic Obstructive Pulmonary Disease Involving P2X7 Receptor by Moraes, Gabriel da Cunha et al.
Research Article
Low-Level Laser Therapy Reduces Lung Inflammation in an
Experimental Model of Chronic Obstructive Pulmonary Disease
Involving P2X7 Receptor
Gabriel da Cunha Moraes,1 Luana Beatriz Vitoretti,1 Auriléia Aparecida de Brito,1
Cintia Estefano Alves,1 Nicole Cristine Rigonato de Oliveira,1 Alana dos Santos Dias,2
Yves Silva Teles Matos,1 Manoel Carneiro Oliveira-Junior ,3 Luis Vicente Franco Oliveira,3
Renata Kelly da Palma,3 Larissa Carbonera Candeo,1 Adriana Lino-dos-Santos-Franco ,1
Anna Carolina Ratto Tempestine Horliana ,1 João Antonio Gimenes Júnior,4
Flavio Aimbire,5 Rodolfo Paula Vieira ,2,6,7 and Ana Paula Ligeiro-de-Oliveira 1
1Post Graduate Program in Biophotonics Applied to Health Sciences, University Nove de Julho (UNINOVE), Sao Paulo, SP, Brazil
2Brazilian Institute of Teaching and Research in Pulmonary and Exercise Immunology (IBEPIPE), São José dos Campos, SP, Brazil
3Experimental Cardiorespiratory Physiology Laboratory, Master’s Degree and PhD Program in Rehabilitation Sciences,
University Nove de Julho (UNINOVE), Sao Paulo, SP, Brazil
4Division of Trauma, Surgical Critical Care, Burns, and Acute Care Surgery, Department of Surgery,
University of California San Diego (UCSD) Health Sciences, San Diego, CA, USA
5Institute of Science and Technology, Federal University of São Paulo (UNIFESP), Sao José dos Campos, SP, Brazil
6Post-graduation Program in Bioengineering, Universidade Brasil, São Paulo, SP, Brazil
7Post-graduation Program in Sciences of Human Movement and Rehabilitation, Federal University of São Paulo (UNIFESP), Santos,
SP, Brazil
Correspondence should be addressed to Ana Paula Ligeiro-de-Oliveira; apligeiro@gmail.com
Received 28 June 2017; Accepted 9 December 2017; Published 4 March 2018
Academic Editor: Saeid Golbidi
Copyright © 2018 Gabriel da Cunha Moraes et al. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work
is properly cited.
Chronic obstructive pulmonary disease (COPD) is a progressive disease characterized by irreversible airflow limitation, airway
inflammation and remodeling, and enlargement of alveolar spaces. COPD is in the top five leading causes of deaths worldwide
and presents a high economic cost. However, there are some preventive measures to lower the risk of developing COPD. Low-
level laser therapy (LLLT) is a new effective therapy, with very low cost and no side effects. So, our objective was to investigate if
LLLT reduces pulmonary alterations in an experimental model of COPD. C57BL/6 mice were submitted to cigarette smoke for
75 days (2x/day). After 60 days to smoke exposure, the treated group was submitted to LLLT (diode laser, 660 nm, 30mW, and
3 J/cm2) for 15 days and euthanized for morphologic and functional analysis of the lungs. Our results showed that LLLT
significantly reduced the number of inflammatory cells and the proinflammatory cytokine secretion such as IL-1β, IL-6, and
TNF-α in bronchoalveolar lavage fluid (BALF). We also observed that LLLT decreased collagen deposition as well as the
expression of purinergic P2X7 receptor. On the other hand, LLLT increased the IL-10 release. Thus, LLLT can be pointed as a
promising therapeutic approach for lung inflammatory diseases as COPD.
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1. Introduction
Chronic obstructive pulmonary disease (COPD) is a global
health problem and has been predicted to become the third
cause of death in the world by 2020 [1]. Cigarette smoking
is currently the major cause of COPD, but recent studies
have described a significant prevalence of COPD among
never-smokers. The estimated annual costs of COPD in
the USA are $50 billion, and most of these costs are related
to exacerbations requiring hospitalization [1, 2]. COPD is
characterized by airflow limitation that is not fully reversible
and is usually progressive and associated with an abnormal
inflammatory response of lungs [3].
Low-level laser therapy (LLLT) has been used clinically
since 1981 in the treatment of patients with inflammatory
pathologies [4]. It is a relatively new and promising approach,
with very low cost, no invasiveness, and no side effects. The
scientific literature has reported anti-inflammatory effects of
LLLT for treating musculoskeletal aches and pains, wound
healing, and chronic and acute inflammation [5]. Further-
more, a growing number of clinical studies are demonstrating
the efficacy and safety of LLLT for different pulmonary
diseases, as asthma and COPD [6, 7]. For instance, some
studies also have demonstrated that the application of LLLT
for the treatment of patients with chronic obstructive
bronchitis accelerates the elimination of clinical symptoms,
increases its efficiency, promotes drainage function of the
bronchi, facilitates standardization of the immune status of
the patient, and contributes to the optimization of lipid
peroxidation [6, 7].
Extracellular ATP has recently gained attention as a dan-
ger signal and important mediator of inflammation via the
activation of purinergic receptors of the P2X (P2X1–P2X7)
and P2Y type (P2Y1, P2Y2, P2Y4, P2Y6, and P2Y11–
P2Y14). During hypoxia, trauma, and infection or inflamma-
tion, extracellular ATP levels can markedly rise, either by
active or by passive release from various cell types, such as
lung epithelial cells and inflammatory cells [8, 9]. ATP neu-
tralization or the inhibition of purinergic receptors can
prevent smoke-induced lung inflammation by reducing neu-
trophil and macrophage infiltration and the release of proin-
flammatory cytokines, such as IL-1β, MIP-2, CXCL1/KC,
IFN-γ, and IL-6 in bronchoalveolar lavage fluid (BALF) [10].
In this study, we provide evidence that LLLT is effective
in reducing lung inflammation, as well as the production
and deposition of collagen in the lung parenchyma of COPD
animals. Moreover, the data suggest that ATP is linked to the
pathogenesis of cigarette smoke-induced COPD, since LLLT
decreased the expression of P2X7 receptor.
2. Material and Methods
2.1. Animals. Female C57BL/6 mice (weight range 19–22 g,
6–8 weeks old) were obtained from the University Nove de
Julho and maintained in a 12h light/dark cycle (lights on at
7:00 a.m. daily), with a controlled temperature at 21± 0.3°C
and relative humidity at 50± 4%, with free access to rodent
food and water. All experiments carried out in this study
were approved by the Animal Care Committee University
Nove de Julho.
2.2. Experimental Model of Cigarette Smoke-Induced
Emphysema. Whole-body cigarette smoke exposure was
performed according to an adapted protocol as described
previously by Peron et al. [11]. Briefly, mice were exposed
to cigarette smoke of 7 commercially available cigarettes
(each one containing 13mg of tar, 1.10mg of nicotine, and
10mg of carbon monoxide) during 75 days, twice a day,
30 minutes each session. Animals exposed to ambient air
served as a control. All experiments were carried out on
day 76.
2.3. Low-Level Laser Treatment Protocol. A diode laser
(power 30mW, energy density of 3 J/cm2 at 660nm of
wavelength) was used. LLLT was performed twice a day,
starting from day 60 up to day 75 of the cigarette smoke
exposure protocol. One hour after each session of cigarette
exposure, the diode laser was applied directly on the skin,
over the trachea and the lung lobes, for 30 seconds each
point, using a small spot size (0.785 cm2). The animals were
divided into three experimental groups: basal (mice exposed
to ambient air), COPD (animals exposed to cigarette smoke
without LLLT), and COPD+LLLT.
2.4. Bronchoalveolar Lavage Fluid. Mice were anaesthetized
and submitted to tracheotomy. Then, the lungs were
flushed 3 times with 0.5ml of PBS each time. The recovery
BALF was centrifuged at 450g, at 4°C, for 15 minutes. The
supernatant fraction was stored at −80°C for further cyto-
kine analysis, and the cell pellet was resuspended in 1.0ml
of PBS. Total cells were counted using a hematocytometer
(Neubauer chamber). Differential cell analyses were per-
formed using a cytocentrifuge (Cytospin) preparation
(200μl of BALF was centrifuged at 300g for 10 minutes).
Cells were stained with the May-Grünwald-Giemsa method,
and 300 cells were counted according to their morphological
characteristics [12, 13].
2.5. Pulmonary Cytokine Levels. Levels of IL-1β, IL-6, CINC-
1/KC, IL-17, TNF-α, and IL-10 were assessed in BALF
supernatants using ELISA kits (R&D Systems, Minneapolis),
according to the manufacturer’s instruction.
2.6. Peribronchial Inflammation Analysis. The space between
the airway basement membrane and adventitia was deter-
mined using Image Pro Plus software as the target field. The
number and type of cells (mononuclear and polymorphonu-
clear cells) were assessed in this specific area. The results were
expressed as number of cells per square millimeter [12].
2.7. Airway Remodeling Assessment by Collagen Deposition.
The lungs were kept in formaldehyde 10% at 20 cmH2O
pressure for 24 hours before inclusion in paraffin. 5μm
sections of the lungs were stained with Sirius Red. The area
between the airway basement membrane and the airway
adventitia was considered the target field, and positive
stained areas (red staining) were evaluated [12, 14].
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2.8. Determination of Emphysema Levels by Alveolar
Enlargement. To measure the alveolar enlargement, sections
of lung tissue were stained with hematoxylin and eosin,
and airspace enlargement was assessed by the mean linear
intercept (Lm) in twenty selected fields per slide, at 200x
magnification [14]. Destruction of alveolar septa was eval-
uated by a point-counting technique in twenty fields ran-
domly throughout the lung parenchyma (excluding fields
presenting airways and pulmonary vessels) [14].
2.9. Western Blotting for P2X7 Receptor. Lung samples were
homogenized in RIPA lysis buffer (Santa Cruz, CA) and cen-
trifuged at 13300 rpm at 4°C for 15minutes. Protein wasmea-
sured by BCA (BCA Protein Assay kit, Thermo Scientific,
USA). 50μg of proteins (which was composed of a pool of
the same amount of proteins of 8 mice from each group)
was loaded in NuPAGE 4–12% Bis-Tri gel (Invitrogen,
USA) and transferred to a nitrocellulose membrane. Primary
antibody anti-P2X7 receptor (sc-15200, Santa Cruz, USA)
was visualized using a horseradish-conjugated secondary
antibody and enhanced by chemiluminescence (Pierce,
Thermo Scientific, USA). An additional probe with β-actin
for control of the amount of proteins was applied using a
monoclonal anti-actin antibody clone C4 (sc-130656, Santa
Cruz, USA). The densitometric analysis of the expression of
the bands was performed using the ImageJ from NIH.
2.10. Lung Mechanics Analysis. The end-inspiratory occlu-
sion after the constant-flow inflation method was used to
assess pulmonary mechanics. The first measurements were
done in a close-chest model, followed by additional mea-
surements in an open-chest model [13, 14]. Then, tracheal
pressure was measured, which reflects transpulmonary
pressure (PL). The initial fast drop in PL (ΔP1) occurs
immediately after end-inspiratory occlusion from the preoc-
clusion corresponding to the inflection point (Pi), followed
by a slow pressure decay (ΔP2) when the plateau is reached,
corresponding to the elastic recoil pressure of the lung (Pel).
ΔP1 significates the dissipated pressure against pulmonary
resistance, while ΔP2 reflects viscoelastic properties (stress
relaxation) [13, 14]. Total pressure drop (ΔPtot) corresponds
to ΔP1+ΔP2. Dynamic elastance (Edyn) and static elastance
(Est) was obtained by dividing Pel and Pi, respectively, by lung
volume (VT). The difference Edyn −Est corresponds to ΔE.
Data analysis was performed with ANADAT software
(RHT-InfoData, Montreal, Canada) [13, 14].
2.11. Statistical Analysis. The normality of the data was tested
by the Shapiro-Wilk test, and the data was analyzed by
one-way analysis of variance (ANOVA) followed by the
Newman-Keuls posttest. Analyses were performed using
GraphPad Prism software 5.0 (GraphPad Software Inc.).
Data are expressed as mean± SD. P values less than 0.05
were considered statistically significant.
3. Results
3.1. LLLT Reduces Leukocytes in BALF and in Lung Tissue.
Data obtained showed that cigarette smoke exposure in
the COPD group promoted a significant increase in total
leukocyte influx in BALF (Figure 1(a)), as well as in the
number of macrophages, neutrophils, and lymphocytes
(Figures 1(b)–1(d)), which was reduced by LLLT.
The same was observed in lung parenchyma, where
the number of mononuclear and polymorphonuclear cells
decreased after LLLT (Figures 2(a) and 2(b)).
3.2. LLLT Reduces Inflammatory Cytokines in the BALF. The
levels of the proinflammatory cytokines IL-6, IL-1β, IL-17,
TNF-α, and CINC-1/KC in BALF supernatants increased
in the COPD group and were significantly reduced by
LLLT. On the other hand, the LLLT was capable to rees-
tablish the levels of the anti-inflammatory cytokine IL-10
that were reduced by the cigarette smoke exposure in the
COPD group (Figure 3).
3.3. LLLT Reduces Collagen Deposition and Alveolar
Enlargement in the Lungs of COPD Animals. We next
decided to verify some possible effects of LLLT on collagen
deposition and on the enlargement of lung parenchyma, both
considered important markers for COPD. Our data demon-
strated that the amount of collagen in the COPD group is
higher than that in the control group. After this, LLLT
significantly decreased the collagen in the airways of all
animals under therapeutic protocol (Figure 4(a)). We also
observed that the LLLT significantly decreases the alveolar
enlargement when compared to the COPD group, indicating
reduced lung emphysema (Figure 4(b)).
3.4. LLLT Reduces the Expression of Purinergic P2X7
Receptor. We analyzed the expression of purinergic P2X7
receptor in lung tissue of mice after cigarette smoke exposure.
The results showed that LLLT significantly reduced the
increase in expression of the purinergic P2X7 receptor in
smoke-induced COPD animals as shown in Figure 5.
3.5. LLLT Increases Lung Mechanics. As shown in Figures 6
and 7, the respiratory system and lung elastance values (Est
and Edyn) measured were reduced in the COPD group when
compared to the basal group. On the other hand, we observed
that the LLLT significantly increases these elastance values.
4. Discussion
The present study showed that the LLLT (660 nm) in an
experimental model reduces the main COPD outcomes,
such as lung emphysema, airway remodeling, and chronic
bronchitis. In addition, the study showed that such effects
were followed by reduced expression of P2X7 receptor,
suggesting LLLT modulating purinergic signaling, a molec-
ular pathway involved in the pathogenesis of COPD. In
summary, LLLT reduced BAL cellularity, proinflammatory
cytokine secretion, collagen deposition, alveolar enlargement,
and the expression of the P2X7 receptor.
Despite cigarette smoking-associated diseases being the
fourth leading cause of death in the United States of America
[15], there is a clear need for new therapies that can prevent
the induction and the progression of COPD [16]. In the
physiopathology of COPD, macrophages and neutrophils
contribute to the lung injury releasing several mediators,
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free radicals, proteases, cytokines, and chemokines [15].
Furthermore, the activation of neutrophils has been directly
linked with COPD severity and mortality. In this way, our
results showed that LLLT was effective to reduce the migra-
tion of these cells into the lungs, as well as to inhibit proin-
flammatory cytokine secretion, reinforcing the beneficial
effects of LLL therapy. Furthermore, some studies have
evaluated the lung inflammation with special emphasis on
airway remodeling. The airway remodeling requires cellular
proliferation, increased deposition of extracellular matrix
proteins, thickening of the basement membrane, collagen
production, and increased mucus secretion [16, 17]. In
our study, we have observed that LLL-treated mice have
displayed a significant reduction in collagen deposition
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Figure 2: Treatment with LLL reduces mononuclear and polymorphonuclear cells in peribronchial space of COPD animals. Quantification of
mononuclear (a) and polymorphonuclear (b) cells in peribronchial space in lung parenchyma. Data are expressed as mean± SD of three
independent experiments. n = 5–8 animals per group. ∗P < 0 05 in relation to the basal group; ϕP < 0 05 in relation to the COPD group.
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Figure 1: Treatment with LLL reduces cellular infiltration in BALF of COPD animals. Quantification of total cells (a), macrophages (b),
neutrophils (c), and lymphocytes (d) in bronchoalveolar lavage fluid. Data are expressed as mean± SD of three independent experiments.
n = 5–8 animals per group. ∗P < 0 05 in relation to the basal group; ϕP < 0 05 in relation to the COPD group.
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and improved alveolar enlargement, which are key features
of COPD. In this context, the laser therapy seems to con-
tribute to the maintenance of integrity of lung structure.
Such beneficial effects of LLLT observed in the present
study were reinforced by functional measurements, as dem-
onstrated by improved static and dynamic elastance, evalu-
ated in both close- and open-chest fashion. These results
are particularly important, since reduced static elastance
and dynamic elastance observed in the present study resem-
ble typical impairment of human COPD and are related to
increased work of breathing, significantly accounting to
COPD severity [18].
The main mechanisms responsible for the modulation of
the inflammatory process triggered by LLLT involve increas-
ing local microcirculation, promotion of angiogenesis, and
immune cell activation leading to accelerated healing [19].
The scientific literature about the effects of LLLT in COPD
is scarce; however, recently we have demonstrated that
the LLLT (660 nm) alone and in association with human
tubal-derived mesenchymal stromal cells reduced cigarette
smoke-induced COPD [11]. Corroborating our findings,
several other groups have already addressed the capacity
of LLLT in modulating lung diseases. Miranda da Silva
et al. [20], in a model of lung inflammation induced by
formaldehyde exposure, demonstrated that LLLT (660 nm)
reduced the number of leukocytes, mast cell degranulation,
myeloperoxidase activity, microvascular lung permeability,
and inflammatory cytokine release. In the same way, Silva
et al. [21] demonstrated that LLLT (660nm) reduced
bronchial hyperresponsiveness, eosinophils and eotaxin,
ICAM expression, and Th2 cytokine release in a model of
experimental allergic lung inflammation. In another study,
Oliveira et al. [22] showed, for the first time, the effects of
LLLT (830 nm) reducing the acute pulmonary inflammation
in a pulmonary and extra pulmonary model of LPS-induced
ARDS in BALB/c mice.
Interestingly, recent reports have shown that LLLT also
exerts its function by increasing intracellular AMPc, thus
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Figure 3: Treatment with LLL reduces proinflammatory cytokine secretion and increases the levels of IL-10 in the BALF of COPD animals.
Quantification of IL-6 (a), IL-1β (b), IL-17 (c), TNF-α (d), KC (e), and IL-10 (f) in bronchoalveolar lavage fluid supernatants. Data are
expressed as mean± SD of three independent experiments. n = 5–8 animals per group. ∗P < 0 05 in relation to the basal group; ϕP < 0 05
in relation to the COPD group.
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suppressing important inflammatory transcription factors as
NF-κB [23]. Moreover, studies showed that ATP was
elevated in BALF of cigarette smoke-exposed mice [24] and
of human cigarette smokers [25]. The P2X7 receptor when
exposed to ATP induces a number of features associated
with COPD pathogenesis, such as neutrophil chemotaxis,
release of proinflammatory cytokines (i.e., IL-1β, IL-6,
and IL-18), reactive oxygen species (ROS), and tissue-
degrading enzymes from neutrophils and macrophages
[25]. In fact, Lommatzsch et al. [25] showed that the
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Figure 4: Treatment with LLL reduces collagen deposition and alveolar enlargement in the lungs of COPD animals. The sections were stained
with Sirius Red for collagen detection (a) and hematoxylin/eosin for alveolar enlargement (b). Data are expressed as mean± SD. ∗P < 0 05 in
relation to the basal group; ϕP < 0 05 in relation to the COPD group.
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Figure 5: Treatment with LLL reduces P2X7 receptor expression in
the lungs of COPD animals. Lung samples were homogenized to
determine the expression of the P2X7 receptor by the Western
blotting technique. ∗P < 0 05 in relation to the basal group;
ϕP < 0 05 in relation to the COPD group.
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Figure 6: Effect of treatment with LLL on static (a) and dynamic (b)
elastance in the respiratory system. The animals were submitted to
the anterior incision of the trachea, followed by cannulation of the
same. Data are expressed as mean± SD. n = 5–8 animals per
group. ∗∗P < 0 01 in relation to the basal group; ϕP < 0 05 in
relation to the COPD group.
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P2X7 receptor is upregulated on BALF macrophages and
blood neutrophils from patients with COPD. In the present
study, we demonstrated for the first time that LLLT reduces
smoke-induced P2X7 receptor expression in lung tissue, sug-
gesting an involvement of this receptor as part of the mecha-
nisms of LLLT reducing smoke-induced COPD in mice.
In summary, our results indicate that LLLT can be a
promising therapy in COPD treatment, as demonstrated in
an experimental model of cigarette smoke-induced COPD
in mice.
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